|
|
Volumn 5, Issue 4, 2005, Pages 292-294
|
|
Cancer and leukemia group b/southwest oncology group trial 80405: A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
a,b
|
|
Author keywords
Bevacizumab; Cetuximab; FOLFIRI; FOLFOX
|
|
Indexed keywords
BEVACIZUMAB;
CETUXIMAB;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
ANTINEOPLASTIC AGENT;
BIOLOGICAL PRODUCT;
CAMPTOTHECIN;
DRUG DERIVATIVE;
FOLFOX PROTOCOL;
IFL PROTOCOL;
MONOCLONAL ANTIBODY;
PLATINUM COMPLEX;
ADULT;
ADVANCED CANCER;
ARTERY THROMBOSIS;
ARTICLE;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CEREBROVASCULAR ACCIDENT;
CHEMOTHERAPY INDUCED EMESIS;
CLINICAL TRIAL;
COLD SENSITIVITY;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DRUG ERUPTION;
DRUG INFUSION;
HAIR LOSS;
HEART INFARCTION;
HUMAN;
HYPERTENSION;
LEUKEMIA;
METASTASIS POTENTIAL;
MUCOSA INFLAMMATION;
NAUSEA;
NEUROPATHY;
NEUTROPENIA;
PHASE 3 CLINICAL TRIAL;
PROTEINURIA;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SURVIVAL RATE;
SURVIVAL TIME;
TREATMENT CONTRAINDICATION;
TREATMENT OUTCOME;
TUMOR GROWTH;
ADENOCARCINOMA;
CANCER STAGING;
COLORECTAL TUMOR;
PATHOLOGY;
ADENOCARCINOMA;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BIOLOGICAL PRODUCTS;
CAMPTOTHECIN;
COLORECTAL NEOPLASMS;
FLUOROURACIL;
HUMANS;
LEUCOVORIN;
NEOPLASM STAGING;
ORGANOPLATINUM COMPOUNDS;
|
|
EID: 33644836082
PISSN: 15330028
EISSN: None
Source Type: Journal
DOI: 10.3816/CCC.2005.n.043 Document Type: Article |
|
Times cited : (28)
|
|
References (10)
|
